Literature DB >> 6371561

Lack of effect of captopril on the sodium retention of the nephrotic syndrome.

E A Brown, N D Markandu, G A Sagnella, B E Jones, G A MacGregor.   

Abstract

The mechanism of sodium retention in the nephrotic syndrome remains controversial, though the classic pathophysiological explanation is stimulation of the renin-angiotensin-aldosterone system. Recent evidence has shown that many patients with the nephrotic syndrome have a normal or low plasma renin activity suggesting that there might be an intrarenal cause for their sodium retention. We gave captopril, an oral angiotensin-converting enzyme inhibitor, during 10 separate episodes of sodium retention in nephrotic syndrome. There was evidence of stimulation of the renin system in 7 of these episodes. Despite a marked fall in plasma aldosterone, all patients continued to retain sodium and water and gain weight. This demonstrates that the sodium retention of nephrotic syndrome is not due to stimulation of the renin-angiotensin-aldosterone system, but must be due to some other mechanism, which is probably intrarenal.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6371561     DOI: 10.1159/000183206

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  11 in total

Review 1.  Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension.

Authors:  Evan C Ray; Helbert Rondon-Berrios; Cary R Boyd; Thomas R Kleyman
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 2.  The nephrotic syndrome.

Authors:  E A Brown
Journal:  Postgrad Med J       Date:  1985-12       Impact factor: 2.401

3.  Over- or underfill: not all nephrotic states are created equal.

Authors:  Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2013-03-26       Impact factor: 3.714

Review 4.  The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications.

Authors:  Melissa A Cadnapaphornchai; Oleksandra Tkachenko; Dmitry Shchekochikhin; Robert W Schrier
Journal:  Pediatr Nephrol       Date:  2013-08-30       Impact factor: 3.714

5.  Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC.

Authors:  René F Andersen; Kristian B Buhl; Boye L Jensen; Per Svenningsen; Ulla G Friis; Bente Jespersen; Søren Rittig
Journal:  Pediatr Nephrol       Date:  2013-03-16       Impact factor: 3.714

Review 6.  Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications.

Authors:  Alain Doucet; Guillaume Favre; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2007-06-07       Impact factor: 3.714

7.  Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome.

Authors:  P A Sjöström; B G Odlind; B A Beermann; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 8.  Human albumin infusion for treating oedema in people with nephrotic syndrome.

Authors:  Jacqueline J Ho; Azreen S Adnan; Yee Cheng Kueh; Nurul Jannah Ambak; Hans Van Rostenberghe; Fauziah Jummaat
Journal:  Cochrane Database Syst Rev       Date:  2019-07-12

Review 9.  Fluid balance concepts in medicine: Principles and practice.

Authors:  Maria-Eleni Roumelioti; Robert H Glew; Zeid J Khitan; Helbert Rondon-Berrios; Christos P Argyropoulos; Deepak Malhotra; Dominic S Raj; Emmanuel I Agaba; Mark Rohrscheib; Glen H Murata; Joseph I Shapiro; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2018-01-06

10.  Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report.

Authors:  Gitte R Hinrichs; Line A Mortensen; Boye L Jensen; Claus Bistrup
Journal:  Physiol Rep       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.